OPRK1 encodes the kappa-opioid receptor (KOR), a seven-transmembrane G protein-coupled receptor (GPCR) that binds endogenous dynorphins and a variety of synthetic and natural ligands. KOR is widely expressed throughout the central and peripheral nervous systems, where it modulates pain perception, mood, reward processing, stress responses, and neuroinflammation[1].
Unlike mu-opioid receptors (encoded by OPRM1) that mediate euphoria and analgesia, KOR activation is associated with dysphoric and anxiogenic effects. This unique pharmacology has made KOR a compelling target for treating substance use disorders, chronic pain, and mood disorders. More recently, KOR signaling has been implicated in Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions through its effects on dopamine signaling, neuroinflammation, and cellular stress responses[2].
| Property | Value |
|---|---|
| Gene Symbol | OPRK1 |
| Protein Name | Kappa-opioid receptor (KOR) |
| Chromosomal Location | 8q11.23 |
| NCBI Gene ID | 4985 |
| UniProt ID | P41145 |
| Protein Length | 426 amino acids |
| Molecular Weight | ~48 kDa |
| Protein Class | Class A GPCR (rhodopsin family) |
| Aliases | KOR, OPRK |
| Tissue Expression | CNS (striatum, cortex, hippocampus, hypothalamus, spinal cord), peripheral sensory neurons, immune cells |
KOR binds the endogenous opioid peptides dynorphin A (1-17), dynorphin A (1-8), and dynorphin B with high affinity and selectivity over mu and delta opioid receptors. Dynorphins are the only known endogenous ligands with significant KOR selectivity; beta-endorphin and enkephalins bind primarily to mu and delta receptors[3].
Exogenous KOR-selective ligands include:
KOR couples primarily to Gαi/Gαo proteins, leading to:
Striatum and basal ganglia: KOR is highly expressed in the striatum, particularly in medium spiny neurons and dopaminergic nerve terminals. KOR activation modulates dopamine release and behavior. It inhibits dopamine release from the substantia nigra pars compacta and ventral tegmental area, contributing to its dysphoric effects and role in addiction[5].
Hypothalamus and HPA axis: KOR activation in the hypothalamus promotes stress responses and dynorphin release feeds back to activate KOR, creating a self-reinforcing stress loop. KOR antagonists can block stress-induced behaviors and drug seeking[3:1].
Hippocampus: KOR is expressed in the hippocampus, particularly in CA1 and dentate gyrus. KOR activation inhibits glutamate release and impairs synaptic plasticity. Dynorphin levels increase with neuronal activity, providing negative feedback on excitability.
Spinal cord and pain pathways: KOR is expressed in the dorsal horn of the spinal cord, where it inhibits pain transmission by reducing glutamate and substance P release from primary afferent neurons[6].
Peripheral sensory neurons: KOR in sensory ganglia modulates nociception and neuropathic pain. KOR agonists reduce pain by acting on peripheral nerve terminals.
The dynorphin-KOR system is distinct from other opioid systems:
Dopaminergic modulation: The dynorphin-KOR system is closely integrated with dopaminergic circuits. In PD, dopaminergic neuron degeneration leads to compensatory changes in dynorphin expression. Studies show elevated dynorphin levels in the striatum and substantia nigra in PD models and patients[7].
KOR-dopamine interactions: KOR activation inhibits dopamine release from terminals in the striatum through presynaptic mechanisms. This creates a feedforward loop: as dopamine neurons degenerate, dynorphin-KOR signaling is dysregulated, further reducing dopamine tone and exacerbating motor symptoms[@chus2019].
Alpha-synuclein interactions: Emerging evidence links KOR signaling to alpha-synuclein (SNCA) pathology. KOR activation may influence the aggregation or clearance of alpha-synuclein, and conversely, alpha-synuclein pathology may alter KOR function[8].
Therapeutic potential: KOR antagonists are being explored to:
Neuroinflammation modulation: The dynorphin-KOR system modulates neuroinflammation through effects on microglia and astrocytes. KOR activation on glial cells can either promote or suppress inflammatory responses depending on cell type and context[10].
Dynorphin elevation in AD: Elevated dynorphin levels have been reported in AD brains, potentially as a compensatory response to synaptic dysfunction and neuronal stress. High dynorphin may contribute to cognitive impairment through KOR-mediated inhibition of synaptic plasticity in the hippocampus[11].
Cognitive effects: KOR activation impairs hippocampal synaptic plasticity, including long-term potentiation (LTP). This is mediated by inhibition of glutamate release and modulation of NMDA receptor function. KOR antagonists have been shown to enhance memory in animal models.
Therapeutic targeting: KOR antagonists could potentially:
Neuropathic pain: KOR is implicated in chronic pain states, including chemotherapy-induced peripheral neuropathy and diabetic neuropathy. KOR agonists have antinociceptive effects at the spinal level, but brain-level KOR activation can produce aversion[6:1].
Stress-induced pain amplification: Chronic stress, which is a risk factor for neurodegeneration, dysregulates the dynorphin-KOR system, amplifying pain sensitivity and contributing to a vicious cycle of stress-pain-inflammation.
Dynorphin and addiction: The dynorphin-KOR system mediates the dysphoric component of addiction withdrawal. KOR activation promotes reinstatement of drug seeking and contributes to the negative emotional state that drives addiction relapse[12].
PARK2 links: Given that dynorphin is processed from PDYN, and PDYN is a transcriptional target of REST (repressor element-1 silencing transcription factor), mutations in PDYN itself could contribute to dynorphin system dysfunction in neurodegeneration.
KOR exhibits ligand bias (functional selectivity), where different ligands preferentially activate different downstream pathways:
This has guided the development of peripherally-restricted KOR agonists (for analgesia without dysphoria) and biased KOR antagonists that block beta-arrestin signaling while preserving potential beneficial effects.
KOR undergoes:
Sustained agonist exposure leads to receptor desensitization and downregulation. This trafficking is modulated by phosphorylation at specific serine and threonine residues in the C-terminal tail.
KOR can form heterodimers with mu (OPRM1) and delta (OPRD1) opioid receptors, creating complexes with unique pharmacological properties. Heterodimerization can alter ligand binding, signal transduction, and trafficking of both partners.
Several KOR antagonists are in development:
Peripherally-restricted KOR agonists like ** asimadoline** have been tested for chronic pain without CNS dysphoric effects.
OPRK1 polymorphisms associated with:
These variants may influence an individual's susceptibility to stress-related disorders, chronic pain, and possibly neurodegenerative disease[15].
KOR subtypes and signaling diversity: Are there functionally distinct KOR populations (e.g., neuronal vs. glial) that could be selectively targeted?
Dynorphin-KOR in PD progression: Is dysregulated dynorphin a cause or consequence of dopaminergic degeneration? Can KOR modulation slow disease progression?
KOR and neuroinflammation: How does KOR signaling on microglia and astrocytes influence the neuroinflammatory response in AD and PD?
Peripherally-restricted strategies: Can peripheral KOR modulation provide therapeutic benefit without CNS dysphoria?
Biased agonism: Can selectively activating G-protein signaling (without beta-arrestin recruitment) provide analgesia without dysphoria?
Combination therapies: Could KOR modulators synergize with dopaminergic drugs in PD or cholinesterase inhibitors in AD?
Kreek MJ, et al. Kappa opioid receptor system in addiction and disease. Neuropsychopharmacology. 2013. ↩︎
Fallon N, et al. Kappa opioid receptor in chronic pain and depression. Neuropsychopharmacology. 2017. ↩︎ ↩︎
Bruchas MR, et al. Stress-activated dynorphin/kappa opioid receptor system in mood and anxiety. Journal of Clinical Investigation. 2011. ↩︎ ↩︎
Land BB, et al. Kappa opioid receptor activation and stress-related disorders. Physiological Reviews. 2018. ↩︎ ↩︎
Prus O, et al. Kappa opioid receptor modulation of dopaminergic circuits. Neuropharmacology. 2019. ↩︎
Metcalf CS, et al. Kappa opioid receptors and pain modulation. Pharmacology Biochemistry and Behavior. 2010. ↩︎ ↩︎
Wang L, et al. Kappa opioid receptor signaling in Parkinson's disease models. npj Parkinson's Disease. 2019. ↩︎
Fan X, et al. Kappa opioid receptor activation and alpha-synuclein pathology. Journal of Neuroscience. 2019. ↩︎
Whittaker E, et al. Kappa opioid receptors in the basal ganglia and movement disorders. Movement Disorders. 2022. ↩︎
Campos FC, et al. Kappa opioid receptors in neuroinflammation and neurodegeneration. British Journal of Pharmacology. 2021. ↩︎
Wagner K, et al. Dynorphin-KOR system in Alzheimer's disease neuroinflammation. Journal of Neuroinflammation. 2020. ↩︎
Shippenberg TS, et al. Kappa-opioid receptor agonists in the treatment of addiction. Biological Psychiatry. 2007. ↩︎
Chern CM, et al. Kappa opioid receptor agonists: therapeutic potential and concerns. Expert Opinion on Investigational Drugs. 2022. ↩︎
Reiner S, et al. Kappa opioid receptor signaling and neuroprotection. Frontiers in Neuroscience. 2018. ↩︎
Bortolato M, et al. Kappa opioid receptor gene variants and psychiatric disorders. American Journal of Medical Genetics Part B. 2007. ↩︎